|
Market Closed -
Euronext Paris
10:25:00 04/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 155.80 EUR | +1.70% |
|
+2.16% | +30.92% |
| 22/10 | Ipsen: Better-than-expected Q3 overshadowed by 2027 Somatuline erosion and arbitration risk |  |
| 22/10 | Ipsen S.A. Upgrades Financial Guidance for the Full-Year 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.41TCr | |||||
| 1,25500Cr | |||||
| 64TCr | |||||
| 51TCr | |||||
| 38TCr | |||||
| 36TCr |
- Stock Market
- Stocks
- IPN Stock
- Charts Ipsen
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
